Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (663)	9/2/2009 9:24:05 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 668

online.wsj.com Apparently some people knew this news was coming out......

To: Icebrg who wrote (663)	9/4/2009 7:31:46 PM
From: kkrramer	Read Replies (1) \| Respond to of 668

"This research opens the possibility of new anti-cancer therapies, specifically the use of RNA interference and of Cyclopamine, a plant product known to block Hedgehog pathway activity. This and other similar molecules can now be considered for future research as a treatment for terminal patients with metastatic disease and to fight resurgent forms of the disease." My understanding is that GDC-0449 is synthetic Cyclopamine. Does anybody know how proprietary and protected Curis/Genentech's formulation is? Ken